Navigation Links
Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
Date:9/23/2011

THOUSAND OAKS, Calif., Sept. 23, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) announced today that data from XGEVA® (denosumab) and Vectibix® (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.  

"The data being presented at the 2011 European Multidisciplinary Cancer Congress reflect Amgen's ongoing commitment to advancing the understanding of cancer and developing novel therapies to treat it," said Willard H. Dere, M.D., senior vice president and international chief medical officer at Amgen.  "New biomarker analyses for Vectibix reinforce the importance of patient selection when EGFR inhibitors are used in metastatic colorectal cancer, while data from the '147 study demonstrate the potential for XGEVA to be the first treatment to prevent the spread of prostate cancer to the bone."

SELECTED ABSTRACTS OF INTERESTIdentified below are selected abstracts of interest on Amgen research. Updated data will be presented at the meeting.


  • Denosumab and Bone Metastasis-free Survival in Men with Castrate-resistant Prostate Cancer: Subgroup Analyses From an International, Double-blind, Randomized, Phase 3 Trial(Abstract 7003) Proffered Papers Session Genitourinary Malignancies – Prostate Cancer on Sunday, Sept. 25, 9:45 a.m. CEST, Hall A3 Data embargoed until 12:01 a.m. CEST on Sept. 24. Data to be highlighted in EMCC press program on Sept. 24 at 8:00 a.m. CEST, Room K21 (Level 1).


  • Denosumab Treatment for Giant Cell Tumor of Bone (GCTB) in Adolescent Patients: Interim Results from a Phase 2 Study(Abstract 32LBA) Proffered Papers Session, Sarcoma on Tuesday, Sept. 27, 11:00 a.m. CEST, Hall T2


  • Pain Outcomes in a Randomized Phase 3 Clinical Trial of Denosumab vs
    '/>"/>


  • SOURCE Amgen
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    2. Amgen to Present at the Morgan Stanley Global Healthcare Conference
    3. Amgen to Present at the Baird Healthcare Conference
    4. Amgen to Present at the Stifel Nicolaus Healthcare Conference
    5. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
    6. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
    7. Amgen Announces Webcast of 2011 Second Quarter Financial Results
    8. Amgen Resolves G-CSF Patent Litigation With Teva
    9. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
    10. Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
    11. Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)...   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... announced positive results from a randomized, double-blind Phase ... for the treatment of edematous fibrosclerotic panniculopathy (EFP), ... trial, all three doses of CCH (low (0.06mg), ... in the appearance of cellulite as measured by ...
    (Date:8/20/2014)... Aug. 20, 2014 The National Association ... latest results achieved by the real-time, pseudoephedrine (PSE) ... National Precursor Log Exchange (NPLEx), automatically blocks unlawful ... down meth offenders and make arrests. Data released ... Kansas blocked the sale of more ...
    (Date:8/20/2014)... NEW YORK , Aug. 20, ... a new market research report is ... The Market for Hospital-Acquired Infection Control ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... and healthcare-associated infections (HAIs), demand has ...
    Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7Kansas's Stop-Sale System Achieves Significant Results In Battle Against Meth 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6
    ... 2007 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc. announced today multiple ... gadolinium),Injection, including an oral presentation of Phase ... Gadolinium And Radiation,Therapy) trial data. The presentations ... the 2007 American Society of Clinical Oncology,Annual ...
    ... Potential Benefit of Unique OROS(R),Formulation, SAN DIEGO, ... abuse,remains an ongoing concern for parents and ... Hyperactivity Disorder,(ADHD). Data presented on Tuesday at ... Association highlighted findings that,long-acting OROS(R) methylphenidate had ...
    Cached Medicine Technology:Pharmacyclics Announces Presentations and Published Abstracts on,Xcytrin at The 2007 American Society of Clinical Oncology Annual,Meeting 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 2New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 3New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 4New Data Suggests Less Abuse-Related Effects For OROS,Methylphenidate 5
    (Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
    (Date:8/21/2014)... care physicians in rural communities do not routinely ... to Penn State medical and public health researchers. ... have limited resources if they seek help., "Rural ... women," said Jennifer S. McCall-Hosenfeld, a primary care ... health sciences, Penn State College of Medicine. "However, ...
    (Date:8/21/2014)... August 21, 2014 Xarelto lawsuit ( ... patients to suffer uncontrollable internal bleeding and other serious ... LLP reports. According to court documents, a wrongful death ... Court, Easter District of New York by the family ... bleeding event that was allegedly caused by Xarelto. Among ...
    (Date:8/21/2014)... (PRWEB) August 21, 2014 The ... manufactured by Boston Scientific has begun in Massachusetts ... bellwether trial. The Rottenstein Law Group LLP, a ... with claims of harm stemming from the implantation ... claim for compensation for injuries suffered at ...
    (Date:8/21/2014)... Annapolis, MD (PRWEB) August 21, 2014 ... real estate organizations to obtain industry-focused data, is ... out healthcare real estate data on the Southeast, ... RevistaMed.com/PropertySearch – the first widely available, ... , The total number of searchable properties, including ...
    Breaking Medicine News(10 mins):Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 2Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 3Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 4Health News:Revista Medical Property Data Now Available for the Mid-Atlantic, Southeast and Midwest Regions 5
    ... , TUESDAY, Feb. 1 (HealthDay News) -- Many black ... interaction stressful and don,t feel physicians give them enough useful ... suggests. The findings stem from a series of focus ... result: doctors are viewed as coming up short when it ...
    ... cancer cells dodge the immune system and promote tumor growth, ... disease. While comparable mechanisms to avoid the immune system have ... study tested human breast tumor cells, putting researchers closer to ... The study, published in the journal Cancer Research , ...
    ... targeted breast biopsies for patients with early breast cancer, ... from undergoing a second breast cancer surgery, a new ... undergo a sentinel lymph node biopsy to determine if ... author of the study. Ultrasound, on its own, ...
    ... , TUESDAY, Feb. 1 (HealthDay News) -- Finally some good ... with their parents behave better, have stronger mental health and ... study. Researchers at Brigham Young University,s School of Family ... to 16. They found that the most popular video games ...
    ... screening for breast cancer delivers consistent rates of cancer detection ... study published online and in the April print edition of ... than mammography at identifying suspicious areas of the breast, it ... lesions, which can result in additional testing and false-positive results ...
    ... published a new international multidisciplinary classification of lung adenocarcinoma, ... The new classification is published in the February ... the official publication of the International Association for the ... rapid advances in lung adenocarcinoma affecting clinical, radiologic, pathologic, ...
    Cached Medicine News:Health News:Study Examines Reasons Some Black Men Avoid Doctors 2Health News:Breast cancer cells outsmart the immune system and thrive 2Health News:Breast cancer cells outsmart the immune system and thrive 3Health News:Microbubble ultrasound and breast biopsies 2Health News:Girls Win When They Play Video Games With Parents: Study 2Health News:Repeat MRI screening for breast cancer results in fewer false positives 2Health News:Lung societies unveil new international classification of lung adenocarcinoma 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: